Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18
Section 36
Remote written informed consent
Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 36 · current to July 24, 2025 · regulation last amended February 27, 2022
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
(1) If a qualified investigator is not able to obtain, in person, the written informed consent of a person to participate in a clinical trial in respect of a COVID-19 medical device for which a COVID-19 medical device authorization has been issued or a COVID-19 drug for which a COVID-19 drug authorization has been issued, the qualified investigator may obtain the written informed consent remotely.
(2) In the case where the person is not able to provide their written informed consent, the qualified investigator may obtain their non-written informed consent if the following conditions are met:
(a) the qualified investigator reads the contents of the informed consent form to the person;
(b) the person provides their informed consent before a witness; and
(c) an attestation by the witness that the person has provided their informed consent is provided to the qualified investigator as soon as feasible.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.